Ajanta Pharma Ltd banner

Ajanta Pharma Ltd
NSE:AJANTPHARM

Watchlist Manager
Ajanta Pharma Ltd Logo
Ajanta Pharma Ltd
NSE:AJANTPHARM
Watchlist
Price: 2 849 INR 1.13% Market Closed
Market Cap: ₹356B

Relative Value

The Relative Value of one AJANTPHARM stock under the Base Case scenario is hidden INR. Compared to the current market price of 2 849 INR, Ajanta Pharma Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AJANTPHARM Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

AJANTPHARM Competitors Multiples
Ajanta Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Ajanta Pharma Ltd
NSE:AJANTPHARM
353.7B INR 6.8 35.1 24.5 27.6
US
Eli Lilly and Co
NYSE:LLY
997.2B USD 15.3 48.3 32.5 34.6
US
Johnson & Johnson
NYSE:JNJ
578.6B USD 6.1 21.6 15 18.4
CH
Roche Holding AG
SIX:ROG
281.1B CHF 4.6 30 12.7 14.8
US
Merck & Co Inc
NYSE:MRK
303.5B USD 4.7 16.6 10.4 12.1
CH
Novartis AG
SIX:NOVN
230.9B CHF 5.3 21.2 13.1 16.8
UK
AstraZeneca PLC
LSE:AZN
216.1B GBP 5.2 32.1 15.3 22.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.7 9.3 11
US
Pfizer Inc
NYSE:PFE
154.7B USD 2.5 19.9 7.4 9.9
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD 2.6 20.8 7.3 9.6
P/E Multiple
Earnings Growth PEG
IN
Ajanta Pharma Ltd
NSE:AJANTPHARM
Average P/E: 25.8
35.1
14%
2.5
US
Eli Lilly and Co
NYSE:LLY
48.3
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
CH
Roche Holding AG
SIX:ROG
30
29%
1
US
Merck & Co Inc
NYSE:MRK
16.6
14%
1.2
CH
Novartis AG
SIX:NOVN
21.2
15%
1.4
UK
AstraZeneca PLC
LSE:AZN
32.1
38%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
7%
1.8
US
Pfizer Inc
NYSE:PFE
19.9
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
20.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Ajanta Pharma Ltd
NSE:AJANTPHARM
Average EV/EBITDA: 43.7
24.5
15%
1.6
US
Eli Lilly and Co
NYSE:LLY
32.5
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
US
Merck & Co Inc
NYSE:MRK
10.4
7%
1.5
CH
Novartis AG
SIX:NOVN
13.1
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.3
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
7%
1.3
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-9%
N/A